BR0013282A - Uso de inibidores de monoamina oxidase para a fabricação de drogas destinadas ao tratamento de obesidade - Google Patents

Uso de inibidores de monoamina oxidase para a fabricação de drogas destinadas ao tratamento de obesidade

Info

Publication number
BR0013282A
BR0013282A BR0013282-9A BR0013282A BR0013282A BR 0013282 A BR0013282 A BR 0013282A BR 0013282 A BR0013282 A BR 0013282A BR 0013282 A BR0013282 A BR 0013282A
Authority
BR
Brazil
Prior art keywords
monoamine oxidase
manufacture
inhibitors
oxidase inhibitors
obesity drugs
Prior art date
Application number
BR0013282-9A
Other languages
English (en)
Inventor
Pierre Rosenzweig
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of BR0013282A publication Critical patent/BR0013282A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "USO DE INIBIDORES DE MONOAMINA OXIDASE PARA A FABRICAçãO DE DROGAS DESTINADAS AO TRATAMENTO DE OBESIDADE". A presente invenção refere-se ao uso de inibidores seletivos reversíveis de monoamina oxidase A (MAO-A), inibidores seletivos reversíveis de monoamina oxidase B (MAO-B) ou inibidores reversíveis misturados de MAO-A e MAO-B na fabricação de drogas destinadas ao tratamento de obesidade.
BR0013282-9A 1999-08-16 2000-08-08 Uso de inibidores de monoamina oxidase para a fabricação de drogas destinadas ao tratamento de obesidade BR0013282A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99116026A EP1078632A1 (en) 1999-08-16 1999-08-16 Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
PCT/EP2000/007917 WO2001012176A2 (en) 1999-08-16 2000-08-08 Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity

Publications (1)

Publication Number Publication Date
BR0013282A true BR0013282A (pt) 2002-04-23

Family

ID=8238777

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013282-9A BR0013282A (pt) 1999-08-16 2000-08-08 Uso de inibidores de monoamina oxidase para a fabricação de drogas destinadas ao tratamento de obesidade

Country Status (22)

Country Link
EP (2) EP1078632A1 (pt)
JP (1) JP2003506485A (pt)
KR (1) KR20020025971A (pt)
CN (1) CN1370067A (pt)
AR (1) AR025244A1 (pt)
AU (1) AU6441900A (pt)
BR (1) BR0013282A (pt)
CA (1) CA2377133A1 (pt)
CZ (1) CZ2002554A3 (pt)
EA (1) EA200200117A1 (pt)
EE (1) EE200200062A (pt)
HK (1) HK1046104A1 (pt)
HU (1) HUP0203601A2 (pt)
IL (1) IL147790A0 (pt)
IS (1) IS6251A (pt)
MX (1) MXPA02001649A (pt)
NO (1) NO20020770L (pt)
PL (1) PL364865A1 (pt)
SK (1) SK2162002A3 (pt)
TR (1) TR200200376T2 (pt)
WO (1) WO2001012176A2 (pt)
ZA (1) ZA200200738B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307182B1 (fr) * 2000-08-01 2005-03-30 Sanofi-Aventis Composition pharmaceutique pour administration transdermique de befloxatone
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
DE10142660A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
DE10142722A1 (de) 2001-08-31 2003-03-27 Aventis Pharma Deutschland GmbH, 65929 Frankfurt C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10142661B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
DE10142662B4 (de) 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142665B4 (de) 2001-08-31 2004-05-06 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-one und ihre Derivate
DE10142667B4 (de) 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE10142668A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
DE10142659A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142666A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
DE10342672A1 (de) * 2003-09-16 2005-04-21 Bayer Chemicals Ag Chirale Phosphane zur Verwendung in asymmetrischen Synthesen
CA2620476A1 (en) 2005-06-02 2006-12-07 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US20070078172A1 (en) * 2005-06-16 2007-04-05 Jenrin Discovery Mao-b inhibitors useful for treating obesity
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009070533A1 (en) * 2007-11-29 2009-06-04 Complegen, Inc. Methods of inhibiting steroyl coa desaturase
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN102267990B (zh) * 2011-06-03 2013-11-13 浙江工业大学 一种2,3-二氢苯并呋喃类衍生物及其制备与应用
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN110511208B (zh) * 2019-08-02 2020-08-25 浙江工业大学 N-2-吡啶基-2,3-二叠氮吲哚啉类化合物及其制备与应用
KR20230075912A (ko) 2021-11-23 2023-05-31 서제표 접이식 안경

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3153092A (en) * 1961-07-17 1964-10-13 Smith Kline French Lab 1-methyl-2-phenylcyclopropylamine derivatives
US3466236A (en) * 1965-11-09 1969-09-09 Eastman Kodak Co Irradiation of aminocyclobutanones
AU5550780A (en) * 1979-04-26 1980-10-30 Merrell Toraude Et Compagnie Alpha-halomethyl amines
FR2724171B1 (fr) * 1994-09-05 1997-01-03 Synthelabo Derives de 3,3a,4,5-tetrahydro-1h-oxazolo(3,4-a)quinolein-1-one, leur preparation et leur application en therapeutique
AU699367B2 (en) * 1995-06-02 1998-12-03 Sanofi-Aventis Isoindole derivatives, their preparation and their application in therapy
WO1997013768A1 (fr) * 1995-10-11 1997-04-17 Synthelabo Composes derives d'oxazolidin-2-one, leur procede de preparation et leur application en therapeutique
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
US6303617B1 (en) * 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
CA2338330A1 (en) * 1998-07-31 2000-02-10 Janus Pharmaceuticals, Inc. Use of moclobemide for treating certain phsychiatric and medical disorders

Also Published As

Publication number Publication date
WO2001012176A2 (en) 2001-02-22
EA200200117A1 (ru) 2002-06-27
WO2001012176A3 (en) 2002-03-21
HUP0203601A2 (hu) 2003-02-28
NO20020770L (no) 2002-04-16
ZA200200738B (en) 2003-03-26
AU6441900A (en) 2001-03-13
EP1210080A2 (en) 2002-06-05
CN1370067A (zh) 2002-09-18
CZ2002554A3 (cs) 2002-05-15
JP2003506485A (ja) 2003-02-18
EE200200062A (et) 2003-04-15
PL364865A1 (pl) 2004-12-27
MXPA02001649A (es) 2002-10-23
KR20020025971A (ko) 2002-04-04
SK2162002A3 (en) 2002-07-02
IS6251A (is) 2002-01-25
IL147790A0 (en) 2002-08-14
CA2377133A1 (en) 2001-02-22
TR200200376T2 (tr) 2002-06-21
NO20020770D0 (no) 2002-02-15
HK1046104A1 (zh) 2002-12-27
AR025244A1 (es) 2002-11-13
EP1078632A1 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
BR0013282A (pt) Uso de inibidores de monoamina oxidase para a fabricação de drogas destinadas ao tratamento de obesidade
DK0714386T3 (da) Vandopløseligt nimesulidsalt og anvendelse deraf til behandling af inflammatoriske lidelser
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR0212921A (pt) Composição farmacêutica com base em fondant
BR0209162A (pt) Método para preparar um amido reticulado, amido reticulado, e, uso do mesmo
BR9911768A (pt) Remédio com efeitos antidepressivos
BR9912508A (pt) Métodos e composições transdérmicas para alìvio da dor
DE69905170T2 (de) Thiazolopyrimidinderivate
BR9807655A (pt) Uso de inibidores de lipase gastrintestinal.
EE04039B1 (et) Farmatseutiline kompositsioon peroraalseks manustamiseks, selle valmistamismeetod ja kasutamine
DE60314722D1 (de) Zusammensetzung für die pharmazeutische oder dietätische verwendung zur bekämpfung von haarausfall
BR0317282A (pt) Derivados de 3h-quinazolin-4-ona
BR9913135A (pt) Formulação oral
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
MXPA05006408A (es) Derivados deuterizados de catecolamina y medicamentos comprendiendo estos compuestos.
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BR0002772A (pt) Uso de ligantes melatoninérgicos na obtenção de composições farmacêuticas pretendidas para a prevenção ou o tratamento de patologias do sistema gastrintestinal
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
WO2003040390A3 (en) Protease assay for therapeutic drug monitoring
BR0011049A (pt) Fenilciclohexanocarboxamidas substituìdas e seu uso como inibidores de absorção de adenosina
TW200602008A (en) Plaster
WO2003037219A3 (de) Verwendung von chitosanmaterialien
BR0212289A (pt) Anticorpos contra caspase-8, preparação e uso do mesmo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]